Immunotherapy News and Research

Latest Immunotherapy News and Research

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Researchers illuminate the molecular landscape and clinical features of rare kidney cancer

Researchers illuminate the molecular landscape and clinical features of rare kidney cancer

New grant program launches to advance therapeutic discovery for follicular lymphoma

New grant program launches to advance therapeutic discovery for follicular lymphoma

Grouping tumors by 'immune archetypes' points the way to personalized immunotherapies

Grouping tumors by 'immune archetypes' points the way to personalized immunotherapies

In vivo generation of engineered CAR T cells can reduce fibrosis and restore cardiac function after heart injury

In vivo generation of engineered CAR T cells can reduce fibrosis and restore cardiac function after heart injury

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

LJI researchers discover how loss of TET enzymes can lead to B cell lymphoma

LJI researchers discover how loss of TET enzymes can lead to B cell lymphoma

High-fiber diet helps melanoma patients to respond better to immunotherapy

High-fiber diet helps melanoma patients to respond better to immunotherapy

High-fiber diet linked with improved survival and response to immunotherapy in melanoma patients

High-fiber diet linked with improved survival and response to immunotherapy in melanoma patients

Peto's paradox offers new insights into cancer risk across mammals

Peto's paradox offers new insights into cancer risk across mammals

Fiber-rich diet may help some melanoma patients to respond to immunotherapy

Fiber-rich diet may help some melanoma patients to respond to immunotherapy

Transcription factor Blimp1 identified as potential target for modulating T-reg activity to treat cancer

Transcription factor Blimp1 identified as potential target for modulating T-reg activity to treat cancer

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

Study may lead to a paradigm shift in the care for adults who relapse from large B-cell lymphoma

Study may lead to a paradigm shift in the care for adults who relapse from large B-cell lymphoma

University of Birmingham launches 5 new major studies focused on management of type 1 diabetes

University of Birmingham launches 5 new major studies focused on management of type 1 diabetes

Study provides a more effective treatment approach to preventing graft-versus-host-disease

Study provides a more effective treatment approach to preventing graft-versus-host-disease

Nanoparticle therapeutic can be a potential new approach for treating malignant pleural effusion

Nanoparticle therapeutic can be a potential new approach for treating malignant pleural effusion

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.